InVera Medical is thrilled to announce the official kick-off meeting for the BioVAS: Biological Micro-Surgical Vessel Advanced Closure System project, funded by the Disruptive Technology Innovation Fund (DTIF) Call 4 at InVera Medical HQ in ATU Innovation Hubs.
This pioneering €4.6 million consortium project, led by InVera Medical, will focus on the development of BioVAS – a microvascular vessel wall intervention specifically designed for treatment of venous leg ulceration. At its core the BioVAS project exemplifies industrial research, aiming to acquire new knowledge and skills that will significantly enhance the treatment of Venous Disease.
We’re honoured to collaborate with esteemed partners – Atlantic Technological University – MET Technology Gateway, University of Galway – NCLA – National Centre for Laser Applications, and ICS Medical Devices in this transformative initiative.
The Disruptive Technology Innovation Fund is a €500 million fund established under the National Development Plan (NDP) in 2018 by the Department of Enterprise, Trade and Employment with administrate support from Enterprise Ireland.
A sincere thank you to the Disruptive Technology Innovation Fund team for their invaluable support. Together with our consortium we are committed to making a lasting impact on Venous Leg Ulcer patient care.
For more information:
“Investigational device not for sale in US or any international markets.”